- Home
- DNTH vs BCYC Comparison
DNTH vs BCYC Comparison
Compare DNTH & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- BCYC
- Stock Information
- Founded
- DNTH 2015
- BCYC 2009
- Country
- DNTH United States
- BCYC United Kingdom
- Employees
- DNTH N/A
- BCYC N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- DNTH Health Care
- BCYC Health Care
- Exchange
- DNTH Nasdaq
- BCYC Nasdaq
- Market Cap
- DNTH 606.2M
- BCYC 566.5M
- IPO Year
- DNTH N/A
- BCYC 2019
- Fundamental
- Price
- DNTH $21.50
- BCYC $8.70
- Analyst Decision
- DNTH Strong Buy
- BCYC Buy
- Analyst Count
- DNTH 8
- BCYC 11
- Target Price
- DNTH $53.00
- BCYC $25.00
- AVG Volume (30 Days)
- DNTH 387.8K
- BCYC 308.3K
- Earning Date
- DNTH 08-07-2025
- BCYC 08-05-2025
- Dividend Yield
- DNTH N/A
- BCYC N/A
- EPS Growth
- DNTH N/A
- BCYC N/A
- EPS
- DNTH N/A
- BCYC N/A
- Revenue
- DNTH $6,524,000.00
- BCYC $25,722,000.00
- Revenue This Year
- DNTH N/A
- BCYC $7.35
- Revenue Next Year
- DNTH N/A
- BCYC N/A
- P/E Ratio
- DNTH N/A
- BCYC N/A
- Revenue Growth
- DNTH 102.36
- BCYC N/A
- 52 Week Low
- DNTH $13.37
- BCYC $6.10
- 52 Week High
- DNTH $32.27
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- DNTH 61.73
- BCYC 61.54
- Support Level
- DNTH $19.90
- BCYC $8.21
- Resistance Level
- DNTH $22.49
- BCYC $9.18
- Average True Range (ATR)
- DNTH 1.43
- BCYC 0.50
- MACD
- DNTH 0.22
- BCYC 0.12
- Stochastic Oscillator
- DNTH 64.11
- BCYC 76.81
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.